ImageneBio Inc (IMA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.85-0.82%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · IMA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 22.3% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| -95.7% |
Growth built into the price is above our model estimate.
The price assumes 117.9 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
IMA — Principal Accounting Officer transition
Dated 2026-06-26
Senior Vice President of Finance and Operations and principal accounting officer — Robert Lally: Mr. Lally resigned and the company plans to search for a replacement.
Why it matters: Updates on cash runway will show if the company can sustain its clinical programs. A strong runway supports ongoing development.
Supportive ifManagement confirms cash runway extends beyond Q1 2028.
Worry ifManagement says cash runway is shorter than they said before.
Why it matters: Success in expanding IMG-007 could boost growth prospects for ImageneBio.
Supportive ifNew clinical trials for IMG-007 are announced for more uses.
Worry ifNo new developments or trials announced for IMG-007 in the next quarter.
Why it matters: Starting this trial would expand the use of IMG-007 and show confidence in its effectiveness.
Supportive ifThe Phase 2 trial in alopecia areata begins as planned in 2026.
Worry ifThe Phase 2 trial in alopecia areata is delayed or canceled.
Why it matters: The cash runway impacts the ability to fund ongoing trials. A strong position supports clinical development.
Supportive ifCash runway is extended into Q1 2028 after the placement.
Worry ifCash runway shortens due to higher expenses or funding problems.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$164 on $10,000 · ±1.6% | How much price usually moves either way. |
| Bad day | $563 loss on $10,000 · 5.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,102 loss on $10,000 · 51.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: If healthcare revenue growth speeds up, it could help ImageneBio's performance. This would signal a better market environment.
Supportive ifHealthcare sector revenue growth shows an increase back toward 10% or higher.
Worry ifHealthcare sector revenue growth continues to slow below 10%.
Why it matters: This presentation may show IMG-007's special benefits. Good feedback may help investors.
Supportive ifPeople liked IMG-007 at the SID Meeting. There was a lot of interest.
Worry ifNegative feedback or lack of interest in IMG-007 at the SID Meeting.
Why it matters: Progress in this study shows how well IMG-007 works and its safety for patients.
Supportive ifThere are good updates on patient enrollment and safety in the long-term study.
Worry ifThere are bad safety reports or slow enrollment in the long-term study.
Why it matters: Expanding IMG-007 into new areas like alopecia areata could boost future revenue. This is a key growth priority.
Supportive ifA press release says clinical trials for IMG-007 in alopecia areata have started.
Worry ifNo announcements or delays in the planned expansion of IMG-007.
Why it matters: A strong CFO can improve financial management and investor confidence. This could affect stock performance.
Supportive ifSince the new CFO was hired, financial management has improved. There are positive changes.
Worry ifAfter the new CFO was hired, there are reports of financial problems.
Why it matters: Safety updates are key for trust in IMG-007. Any problems could affect its progress.
Worry ifNo new safety concerns reported in ongoing studies of IMG-007.
Less concerning ifThere are reports of serious safety issues with IMG-007.
Why it matters: Updates will provide insights into the safety and efficacy of IMG-007 over time. This is key for investor confidence.
Watch forUpdates from the long-term study show IMG-007 is safe and effective.
Also watch forNew updates from the long-term study raise concerns. People worry about IMG-007's safety and effectiveness.
Why it matters: Starting this trial would expand the use of IMG-007 into a new indication. This could increase its market potential.
Supportive ifImageneBio begins the Phase 2 trial for IMG-007. This trial is for alopecia areata.
Worry ifImageneBio pushes back the start of the Phase 2 trial for IMG-007. This trial is for alopecia areata.
Why it matters: Topline data will show how well IMG-007 works for atopic dermatitis. This could impact future development and investor confidence.
Supportive ifThe Phase 2b ADAPTIVE trial shows big gains in EASI scores.
Worry ifThe data shows no big gains in EASI scores from the baseline.
Why it matters: Maintaining a strong cash position is crucial for funding ongoing trials. A drop could signal financial issues.
Worry ifCash and equivalents remain above $130 million after Q3 2026.
Less concerning ifCash and equivalents fall below $130 million. This may mean funding problems.